Review decision – February 2018
Decision to update in an on-going clinical guideline
The Institute was proposing to undertake a partial update of the clinical guideline on Crohn's disease: management (CG152). During surveillance a considerable amount of evidence was identified which assessed the efficacy of anti-TNF therapy for maintenance of remission of Crohn’s disease after surgery.
Responses received from stakeholders during the consultation suggested that this may not be the most appropriate course of action.
Stakeholders have indicated that they do not consider an update of TA187 within the forthcoming clinical guideline to be appropriate as any such update would have led to the funding direction for infliximab and adalimumab mandated in TA187 being removed. After further consideration in discussion with the developer, it has been agreed that the partial update of CG152 will incorporate the recommendations from TA187, thus preserving the funding direction.
After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided that TA187 should be not be updated in an on-going clinical guideline
Consequently, TA187 will not be updated and replaced in the update of CG152. The guidance will remain on the static list and the recommendations will be incorporated into the forthcoming clinical guideline.
This page was last updated: 28 February 2018